首页 | 本学科首页   官方微博 | 高级检索  
检索        


213Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells
Institution:1. Department of Otolaryngology Head and Neck Surgery, Technische Universität München, Munich, Germany;2. Department of Nuclear Medicine, Technische Universität München, Munich, Germany;3. Department of Radiotherapy, Technische Universität München, Munich, Germany;4. Department of Gynecology and Obstetrics University of Regensburg, Regensburg, Germany;5. Institute for Transuranium Elements, European Commission, Joint Research Centre, Karlsruhe, Germany;1. Department of Nuclear Medicine, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands;2. Graduate School of Neurosciences, Amsterdam, The Netherlands;3. Department of Nuclear Medicine, Medical Center Alkmaar, Alkmaar, The Netherlands;4. Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, The Netherlands;5. Department of Anatomy and Neurosciences, VU Medical Center, Amsterdam, The Netherlands;1. Institute of Neuroscience and Medicine, INM-2, Forschungszentrum Jülich GmbH, Jülich, Germany;2. Institute of Neuroscience and Medicine, INM-4, Forschungszentrum Jülich GmbH, Jülich, Germany;3. Neurological Department, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
Abstract:IntroductionTreatment of patients with squamous cell carcinoma of head and neck is hampered by resistance of tumor cells to irradiation. Additional therapies enhancing the effect of X-ray irradiation may be beneficial. Antibodies targeting EGFR have been shown to improve the efficacy of radiation therapy. Therefore, we analyzed cytotoxicity of 213Bi-anti-EGFR immunoconjugates in combination with X-ray irradiation.MethodsThe monoclonal anti-EGFR antibody matuzumab was coupled to CHX-A”-DTPA forming stable complexes with 213Bi. Cytotoxicity of X-ray radiation, of treatment with 213Bi-anti-EGFR monoclonal antibodies (MAb) or of a combined treatment regimen was assayed using cell proliferation and colony formation assays in UD-SCC5 cells. Key proteins of cell-cycle arrest and cell death were examined by Western blot analysis. Cell cycle analysis was performed by flow cytometry. DNA double-strand breaks were detected via γH2AX and quantified using Definiens? software.ResultsIrradiation with X-rays or treatment with 213Bi-anti-EGFR-MAb resulted in median lethal dose (LD50) values of 12 Gy or 130 kBq/mL, respectively. Treatment with 37 kBq/mL of 213Bi-anti-EGFR-MAb or 2 Gy of X-rays had only little effect on colony formation of UD-SCC5 cells. In contrast, a combined treatment regimen (37 kBq/mL plus 2 Gy) significantly decreased colony formation and enhanced the formation of DNA double-strand breaks. As revealed by flow cytometry, radiation treatments caused accumulation of cells in the G0/G1 phase. Both treatment with 213Bi-anti-EGFR immunoconjugates and application of the combined treatment regimen triggered activation of genes of signaling pathways involved in cell-cycle arrest and induction of apoptosis like p21/Waf, GADD45, Puma and Bax, which were only marginally modulated by X-ray irradiation of cells.Conclusions213Bi-anti-EGFR-MAb enhances cytotoxicity of X-ray irradiation in UD-SCC5 cells most probably due to effective induction of DNA double-strand breaks. Induction of genes involved in cell-cycle arrest and cell death is almost exclusively due to 213Bi-anti-EGFR-MAb and seems to be independent of p53 function.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号